Halbert Hargrove Global Advisors LLC Invests $47,000 in Novo Nordisk A/S (NYSE:NVO)

Halbert Hargrove Global Advisors LLC purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, HoldingsChannel.com reports. The fund purchased 549 shares of the company’s stock, valued at approximately $47,000.

Several other institutional investors have also modified their holdings of the stock. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Novo Nordisk A/S during the 4th quarter worth $107,000. Smartleaf Asset Management LLC raised its holdings in shares of Novo Nordisk A/S by 88.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 17,788 shares of the company’s stock worth $1,525,000 after acquiring an additional 8,351 shares during the period. Tower View Wealth Management LLC raised its holdings in shares of Novo Nordisk A/S by 5.8% during the 4th quarter. Tower View Wealth Management LLC now owns 25,035 shares of the company’s stock worth $2,154,000 after acquiring an additional 1,379 shares during the period. Nixon Peabody Trust Co. raised its holdings in shares of Novo Nordisk A/S by 38.6% during the 4th quarter. Nixon Peabody Trust Co. now owns 2,874 shares of the company’s stock worth $247,000 after acquiring an additional 800 shares during the period. Finally, SVB Wealth LLC purchased a new position in shares of Novo Nordisk A/S during the 4th quarter worth $1,250,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Morgan Stanley assumed coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. BMO Capital Markets reduced their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $90.68 on Friday. The company has a market cap of $406.91 billion, a P/E ratio of 27.56, a P/E/G ratio of 0.90 and a beta of 0.45. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The stock has a 50-day moving average of $84.82 and a two-hundred day moving average of $106.72. Novo Nordisk A/S has a 1-year low of $77.82 and a 1-year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be given a dividend of $0.7874 per share. The ex-dividend date of this dividend is Monday, March 31st. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s payout ratio is currently 47.72%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.